MCM2 and Ki-67 expression in human lung adenocarcinoma: Prognostic implications

Pathobiology

Volumn 71, Issue 4, 2004, Pages 193-200

  Hashimoto, Kiyoshi ^a   Araki, Kunio ^a   Osaki, Mitsuhiko ^a,b   Nakamura, Hiroshige ^d   Tomita, Katsuyuki ^c   Shimizu, Eiji ^c   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d National Hospital Organization   (Japan)

Author keywords

Ki 67; Lung adenocarcinoma; Minichromosome maintenance protein 2 (MCM2); p53

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; PROTEIN; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL LABELING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; TUMOR CELL; WESTERN BLOTTING;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 3242788775     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078673     Document Type: Article

References (49)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 2001;37(Suppl 8):S4-S66.
2. Ginsberg RJ, Vokes EE, Rabin A: Non-small cell lung cancer; in Devita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 855-911.
3. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI: Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-2503.
4. Ishida T, Kaneko S, Akazawa K, Tateishi M, Sugio K, Sugimachi K: Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 1993;53:5000-5003.
5. 1 cyclins in cell proliferation and prognosis. Cancer Res 2001;61:2500-2504.
6. Diez M, Maestro ML, Torres A, Hernando F, Ortega MD, García-Asenjo JA, Picardo A, Muguerza JM, Sanchez-Pernaute A, Balibrea JL: Epidermal growth factor receptor in non-small cell cancer of the lung. Arch Bronconeumol 1994;30:282-286.
7. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY, Gong K: Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I nonsmall cell lung cancer. Clin Cancer Res 2002;8: 3796-3802.
8. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY: Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3669-3675.
9. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR: hTERT expression is a prognostic factor of survival in patients with stage I nonsmall cell lung cancer. Clin Cancer Res 2002;8: 2883-2889.
10. Thommes P, Fett R, Schray B, Burkhart R, Barnes M, Kennedy C, Brown NC, Knippers R: Properties of the nuclear P1 protein, a mammalian homologue of the yeast Mcm3 replication protein. Nucleic Acids Res 1992;20:1069-1074.
11. Kearsey SE, Maiorano D, Holmes EC, Todorov IT: The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 1996;18:183-190.
12. Chong JP, Thommes P, Blow JJ: The role of MCM/P1 proteins in the licensing of DNA replication. Trends Biochem Sci 1996;21:102-106.
13. Tye BK: MCM proteins in DNA replication. Annu Rev Biochem 1999;68:649-686.
14. Nishitani H, Lygerou Z, Nishimoto T, Nurse P: The Cdt1 protein is required to license DNA for replication in fission yeast. Nature 2000; 404:625-628.
15. Maiorano D, Moreau J, Mechali M: XCDT1 is required for the assembly of pre-replicative complexes in Xenopus laevis. Nature 2000;404: 622-625.
16. Ishimi Y, Komamura Y, You Z, Kimura H: Biochemical function of mouse minichromosome maintenance 2 protein. J Biol Chem 1998;273:8369-8375.
17. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-2132.
18. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty TD: Minichromosome maintenance protein 2 expression in prostate: Characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001;7: 2712-2718.
19. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH: Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki-67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001;27:305-313.
20. Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H, Ito H: Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis. Int J Mol Med 2002;10:161-168.
21. Krüger S, Thorns C, Stocker W, Müller-Kunert E, Bohle A, Feller AC: Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder. Eur Urol 2003;43:138-145.
22. Todorov IT, Werness BA, Wang HQ, Buddharaju LN, Todorova PD, Slocum HK, Brooks JS, Huberman JA: HsMCM2/BM28: A novel proliferation marker for human tumors and normal tissues. Lab Invest 1998;78:73-78.
23. Kodani I, Shomori K, Osaki M, Kuratate I, Ryoke K, Ito H: Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cellcycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology 2001;69:150-158.
24. UICC: Lung and pleural tumours; in Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumours. New York, Wiley & Sons, 2002, pp 97-107.
25. Travis WD, Colby TV, Corrin B, Shimasato Y, Brambilla E: Histological Typing of Lung and Pleural Tumours, ed 3, revised. Berlin, Springer, 1999.
26. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
27. Masai H, Matsui E, You Z, Ishimi Y, Tamai K, Arai K: Human Cdc7-related kinase complex: In vitro phosphorylation of MCM by concerted actions of Cdks and Cdc7 and that of a criticial threonine residue of Cdc7 bY Cdks. J Biol Chem 2000;275:29042-29052.
28. Jiang W, McDonald D, Hope TJ, Hunter T: Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J 1999;18:5703-5713.
29. Liu YY, Chen YM, Huang MH, Perng RP: Prognosis and recurrent patterns in bronchioloalveolar carcinoma. Chest 2000;118:940-947.
30. Rena O, Papalia E, Ruffini E, Casadio C, Filosso PL, Oliaro A, Maggi G: Stage I pure bronchioloalveolar carcinoma: Recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardiothorac Surg 2003;23:409-414.
31. Volpino P, D'Andrea N, Cangemi R, Mingazzini P, Cangemi B, Cangemi V: Bronchioloalveolar carcinoma: Clinical, radiographic, and pathological findings. Surgical results. J Cardiovasc Surg (Torino) 2001;42:261-267.
32. Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS, Bepler G: MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 2001;19:4259-4266.
33. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
34. Alexiou C, Onyeaka CV, Beggs D, Akar R, Beggs L, Salama FD, Duffy JP, Morgan WE: Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg 2002; 21:319-325.
35. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986;4:1604-1614.
36. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986;4:14-22.
37. Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer RM Jr: Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994;108: 153-157.
38. Caltagirone S, Ranelletti FO, Rinelli A, Maggiano N, Colasante A, Musiani P, Aiello FB, Piantelli M: Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-smallcell lung cancer. Am J Respir Cell Mol Biol 1997;17:51-59.
39. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-239.
40. Mukhopadhyay T, Roth JA: Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997;14:379-384.
41. Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, Bucciarelli E, Darwish S, Ludovini V, Pistola L, Gregorc V, Tonato M: Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000;74:53-60.
42. Rigau V, Molina TJ, Chaffaud C, Huchon G, Audouin J, Chevret S, Brechot JM: Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer 2002;38:169-176.
43. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H: Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124-7129.
44. Koppe MJ, Zoetmulder FA, van Zandwijk N, Hart AA, Baas P, Rutgers EJ: The prognostic significance of a previous malignancy in operable non-small cell lung cancer. Lung Cancer 2001;32:47-53.
45. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H: Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-244.
46. Fisher DE: Pathways of apoptosis and the modulation of cell death in cancer. Hematol Oncol Clin North Am 2001;15:931-956.
47. Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M: Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 2003;23:2829-2836.
48. Minami K, Saito Y, Imamura H, Okamura A: Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002;38:51-57.
49. Brechot JM, Molina T, Theobald S, Depierre A, Lagrange JL, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Breton JL, Douillard JY, Grivaux M, Jacoulet P, Khalil A, Lemarie E, Martinet Y, Massard G, Milleron B, Moro-Sibilot D, Paesmans M, Pujol JL, Quoix AE, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet PJ, Spaeth D, Stcebner-Delbarre A; FNCLCC, CRLCC: 2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer (in French). Bull Cancer 2002;89: 857-867.